Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM

Haemophilia

Volumn 20, Issue 6, 2014, Pages 777-783

  Iorio, Alfonso ^a   Marcucci, M ^a,b   Cheng, J ^a,c   Oldenburg, J ^d   Schoenig Diesing, C ^e   Matovinovic, E ^e   Romanov, V ^e   Thabane, L ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MILAN   (Italy)

^c ST JOSEPH S HEALTH CENTRE   (Canada)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Bleeding rate; Factor VIII; Factor VIII inhibitors; Hemophilia A; Post marketing; Surveillance

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; RECOMBINANT PROTEIN;

ALLERGIC REACTION; ANEMIA; ANXIETY; ARTICLE; ASTHENIA; AUSTRALIA; BEHAVIOR DISORDER; BLEEDING; BRAIN HEMORRHAGE; CATHETER INFECTION; DRUG EFFICACY; DRUG SAFETY; EDEMA; EUROPE; HEMOPHILIA A; HUMAN; ITALY; JAPAN; LIVER CANCER; LIVER DYSFUNCTION; LUNG CANCER; META ANALYSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RASH; UNITED STATES; COMPLICATION; HEMORRHAGE; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84932088974     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12480     Document Type: Article

References (33)

1. Gouw SC, van der Bom JG, Marijke van den Berg H. Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
2. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
3. Iorio A, Halimeh S, Holzhauer S et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8: 1256-65.
4. Xi M, Makris M, Marcucci M, Santagostino E, Mannucci PM, Iorio A. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost 2013; 11: 1655-62.
5. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
6. Goudemand J, Rothschild C, Demiguel V et al. FVIII-LFB and Recombinant FVIII study groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
7. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 2011; 9: 2180-92.
8. Gouw SC, van der Bom JG, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
9. U.S. Department of Health and Human Services Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER) Guidance for Industry Postmarketing Studies and Clinical Trials - Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act. Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm172001.pdf. Accessed April 2011.
10. European Medicines Agency. Report of Expert Meeting on Factor VIII Products and Inhibitor Development. London, European Medicines Agency, 2007.
11. Aledort LM. Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment. J Thromb Haemost 2011; 9: 423-7.
12. Iorio A, Marcucci M, Makris M. Concentrate-related inhibitor risk: is a difference always real? J Thromb Haemost 2011; 9: 2176-9.
13. Weinstein M, Makris M, Ludlam CA. Biovigilance and pharmacovigilance for haemophilia. Haemophilia 2010; 16(Suppl 5): 17-21.
14. White GC, DiMichele D, Mertens K et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81: 462.
15. Makris M, Calizzani G, Fischer K et al. EUHASS: the European Haemophilia Safety Surveillance system. Thromb Res 2011; 127(Suppl 2): S22-5.
16. Ewenstein BM, Gomperts ED, Pearson S, O'Banion ME. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study. Haemophilia 2004; 10: 491-8.
17. Pollmann H, Externest D, Ganser A et al. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 2007; 13: 131-43.
18. Musso R, Santagostino E, Faradji A et al. KOGENATE Bayer European PMS Study Group. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2008; 99: 52-8.
19. ClinicalTrials.govIdentifier NCT00214734
20. Tarantino MD, Collins PW, Hay CRM et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-37.
21. Blanchette VS, Shapiro AD, Liesner RJ et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-26.
22. Négrier C, Shapiro A, Berntorp E et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of ADVATE in previously treated patients. Thromb Haemost 2008; 100: 217-23.
23. Bacon CL, Singleton E, Brady B et al. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®). Haemophilia 2011; 17: 407-11.
24. Valentino LA, Mamonov V, Hellmann A et al. Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
25. Auerswald G, Thompson AA, Recht M et al. Experience of ADVATE rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost 2012; 107: 1072-82.
26. Shapiro A, Romanov V, Silvati-Fidell L, Wong WY, Schoenig-Diesing C. Integrated Analysis of Safety Data from 12 clinical interventional studies of a Plasma-and Albumin-free Recombinant Factor VIII (rAHF-PFM) in Persons with Hemophilia A (HemoA). Abstracts of the XXIV Congress of the International Society on Thrombosis and Haemostasis. June 29-July 4, 2013. Amsterdam, The Netherlands. J Thromb Haemost 2013; 11(Suppl 2): 1-1322.
27. Oldenburg J, Goudemand J, Valentino L et al. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice. Haemophilia 2010; 16: 866-77.
28. Taki M, Fukutake K, Hanabusa H, Takamatsu J, Shima M, Shirahata A. Postauthorization safety surveillance (PASS) program of antihemophilic factor (recombinant), plasma/albumin-free method (rAHFPFM) for Japanese hemophilia A patients. Abstracts of the XXII Congress of the International Society of Thrombosis and Haemostasis. Boston, Massachusetts, USA. July 11-16, 2009. J Thromb Haemost 2009; 7(Suppl 2): 1-1204.
29. Fukutake K, Hanabusa H, Taki M et al. The post-authorization safety surveillance (pass) program confirmed actual clinical safety and efficacy of recombinant plasma/albumin-free method factor VIII in Japan. Abstracts of the XXIII Congress of the International Society on Thrombosis and Haemostasis with the 57th Annual SSC (Scientific and Standardization Committee) Meeting. July 23-28 2011. Kyoto, Japan. J Thromb Haemost 2011; 9(Suppl 2): 1-1055.
30. Fukutake K, Hanabusa H, Taki M et al. A prospective post-authorization safety surveillance study in 384 hemophilia A patients with antihemophilic factor (recombinant) plasma/albumin free method demonstrates safety and efficacy in Japan. Abstracts of the XXIV Congress of the International Society on Thrombosis and Haemostasis. June 29-July 4, 2013. Amsterdam, The Netherlands. J Thromb Haemost 2013; 11(Suppl 2): 1-1322.
31. Schino M, Rocino A, Santagostino E, Mazzucconi MG. P.I.S.A.-safety, immunogenicity and efficacy of a full length DNA rAHF-PMF in patients with hemophilia A in the Italian post-marketing surveillance study. Abstracts of the XXIV Congress of the International Society on Thrombosis and Haemostasis. June 29-July 4, 2013. Amsterdam, The Netherlands. J Thromb Haemost 2013; 11(Suppl 2): 1-1322.
32. Chen Y, Cheng S, Chang P. The safety and efficacy surveillance study of full-length plasma and albumin-free recombinant factor VIII for previously treated patients with hemophilia A in Taiwan. Abstracts of the XXX International Congress of the World Federation of Hemophilia. July 8-12, 2012. Paris, France. Haemophilia 2012; 18(Suppl 3): 1-226.
33. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII: C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 1998; 79: 872-5.